Elevated plasma levels of CXCL16 in severe COVID-19 patients Sandra P. Smieszek<sup>1</sup>, Vasilios M. Polymeropoulos<sup>1</sup>, Christos M. Polymeropoulos<sup>1</sup>, Bartlomiej P. Przychodzen<sup>1</sup>, Gunther Birznieks<sup>1</sup>, Mihael H. Polymeropoulos<sup>1</sup> <sup>1</sup> Vanda Pharmaceuticals Inc., Washington, DC, USA Corresponding author sandra.smieszek@vandapharma.com **Declarations:** Funding: no relevant funding Conflicts of interest/Competing interests (include appropriate disclosures): authors are employees of Vanda Pharmaceuticals Inc. Availability of data and material (data transparency): Data available upon request Code availability (software application or custom code): not applicable Authors' contributions (optional: please review the submission guidelines from the journal whether statements are mandatory): not applicable Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals: not applicable Ethics approval (include appropriate approvals or waivers): Advarra IRB; Pro00043096 Consent to participate (include appropriate statements): All participants were consented prior to participation Consent for publication (include appropriate statements): not applicable 

38 39 40 **Abstract** 41 Genome-wide association studies have recently identified 3p21.31, with lead variant pointing to 42 the CXCR6 gene, as the strongest thus far reported susceptibility risk locus for severe 43 manifestation of COVID-19. In order the determine its role, we measured plasma levels of Chemokine (C \( \subseteq X \subseteq C \) motif) ligand 16 (CXCL16) in the plasma of COVID-19 hospitalized 44 45 patients. CXCL16 interacts with CXCR6 promoting chemotaxis or cell adhesion. The CXCR6/CXCL16 axis mediates homing of T cells to the lungs in disease and hyper-expression is 46 associated with localised cellular injury. To characterize the CXCR6/CXCL16 axis in the 47 pathogenesis of severe COVID-19, plasma concentrations of CXCL16 collected at baseline from 48 115 hospitalized COVID-19 patients participating in ODYSSEY COVID-19 clinical trial were 49 assessed together with a set of controls. We report elevated levels of CXCL16 in a cohort of 50 COVID-19 hospitalized patients. Specifically, we report significant elevation of CXCL16 plasma 51 levels in association with severity of COVID-19 (as defined by WHO scale) (P-value<0.02). Our 52 current study is the largest thus far study reporting CXCL16 levels in COVID-19 hospitalized 53 54 patients (with whole-genome sequencing data available). The results further support the significant role of the CXCR6/CXCL16 axis in the immunopathogenesis of severe COVID-19 55 56 and warrants further studies to understand which patients would benefit most from targeted 57 treatments. 58 59 Introduction 60 Genome-wide association studies have recently identified 3p21.31, encompassing the CXCR6 61 62 gene, as the strongest thus far reported susceptibility region associated with a severe manifestation of COVID-19 (rs73064425, OR=2.14, P-value=4.77E-30)<sup>1</sup>. Another lead severity 63 variant rs10490770:T>C pointing to CXCR6 was also reported with a P-value of 1.443E-73 64 (hospitalization) and 2.20E-61 (critical illness) by the COVID-19 Host Genetics Initiative<sup>2</sup>. 65 Nakanishi et al., reported that risk allele (rs10490770) carriers experienced an increased risk of 66 COVID-19 related mortality (HR 1.5, 95% CI 1.3-1.8)<sup>3</sup>. Risk allele carriers had increased odds 67 of several COVID-19 complications: severe respiratory failure (OR 2.0, 95% CI 1.6-2.6), venous 68 thromboembolism (OR 1.7, 95% CI 1.2-2.4)<sup>3</sup>. 69

Chemokine ( $C \square X \square C$  motif) ligand 16 (CXCL16) is synthesized as a transmembrane molecule that is expressed as a cell surface-bound molecule, and as a soluble chemokine<sup>4</sup>. CXCL16 interacts with CXCR6 in leukocytes and other cells promoting chemotaxis or cell adhesion. It has been shown that inflammatory cytokines such as IFNγ and TNFα promote CXCL16 expression<sup>5</sup>. CXCL16 has been previously implicated in the pathogenesis of lung injury upon which it is released and functions as a chemoattractant for CXCR6+ T, natural killer (NK), B, and dendritic cells<sup>6</sup>. CXCL16 levels were elevated in the serum of acute lung injury patients in comparison to controls<sup>6</sup>. CXCR6 is expressed on T cells not only in T helper type 1 (Th1) inflammation but also in Th2 inflammation, where it is increased after allergen challenge. It was previously shown that reduction in CD8+ T-lymphocytes occurred between C57BL/6 and CXCR6KO mice<sup>7</sup>. CXCR6 is a major coreceptor of HIV type 2 variants<sup>8</sup>. The CXCR6/CXCL16 axis mediates homing of T cells to the lungs in disease and when hyper expressed is associated with localized cellular injury<sup>7</sup>. This CXCR6/CXCL16 axis is involved in lung pathology also associated with other infections, including influenza. Antagonism was reported to result in reduced inflammation<sup>6</sup>. In a recent report authors have shown thatknockdown of CXCR6 reversed the effect of CXCL16 and so did the treatment with the p38 inhibitor SB203580 abolished the effects of CXCL16<sup>6</sup>. Another recent study has shown that the absence of CXCR6 significantly decreases airway CD8 resident memory T cells due to altered trafficking of CXCR6-/- cells within the lung<sup>9</sup>, Moreover mice lacking CXCL16 also had decreased CD8 resident memory T cells in the airways and ultimately blocking CXCL16 resulted in the inhibition of the steady-state maintenance of airway resident memory T cells<sup>9</sup>.

91

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

### Methods

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

**Participants** 

ODYSSEY is a double-blinded Phase 3 study with a planned randomization of a total of 300 hospitalized severely ill COVID-19 patients (Clinicaltrials.gov: NCT04326426). Inclusion criteria for the study comprised of: 1. Adults aged 18-90; 2. confirmed laboratory COVID-19 infection; 3. confirmed pneumonia by chest radiograph or computed tomography; 4. fever defined as temperature  $\geq 36.6$  °C armpit,  $\geq 37.2$  C oral, or  $\geq 37.8$  °C rectal since admission or the use of antipyretics; 5. PaO2 / FiO2  $\leq$  300; 6. In patient hospitalization. Patients were to be followed for up to 28 days to record clinical outcomes. Patients' clinical progress was recorded on a 7 point clinical status ordinal scale defined as follows: 1- Death; 2- Hospitalized on mechanical ventilation or ECMO; 3- Hospitalized on non invasive ventilation or high-flow oxygen supplementation; 4- Hospitalized requiring supplemental oxygen; 5- Hospitalized not requiring supplemental oxygen, requiring continued medical care; 6- Hospitalized not requiring supplemental oxygen, not requiring continued medical care; 7- Not hospitalized. Main Exclusion Criteria included: 1. Inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements; 2. Known allergy to tradipitant or other neurokinin-1 antagonists; 3. Pregnancy; 4. Uncontrolled HIV, HBV, or HCV infection; 5. Other uncontrolled medically significant diseases; 6. Enrollment in another clinical trial of an investigational therapy; 7. Alanine aminotransferase > 5X Upper Limit of Normal or Creatinine clearance < 50 m 174 l/min; 8. Requiring mechanical ventilation for > 72 hours.

### CXCL16 measurement

To characterize the CXCR6/CXCL16 axis in the pathogenesis of severe COVID-19, plasma concentrations of CXCL16 from 115 hospitalized COVID-19 patients participating in ODYSSEY COVID-19 clinical trial ((NCT04326426)) and additionally samples from 37 controls were assessed. CXCL16 levels in plasma were determined with an enzyme□linked immunosorbent assay (ELISA) assay (Thermofisher ID: # EHCXCL16) performed on plasma collected at baseline in cases and in a set of healthy controls (assay range 2.74-2000 pg/mL).

## Genetic Analysis

Incoming nucleic acid samples are quantified using fluorescent-based assays (PicoGreen) to accurately determine whether sufficient material is available for library preparation and sequencing. DNA sample size distributions are profiled by a Fragment Analyzer (Advanced Analytics) or BioAnalyzer (Agilent Technologies), to assess sample quality and integrity. HumanCoreExome 24v1.3 array was performed on all human DNA samples sequenced. Whole genome sequencing (WGS) libraries were prepared using the Truseq DNA PCR-free Library Preparation Kit. Whole Genome data were processed on NYGC automated pipeline. Paired-end 150 bp reads were aligned to the GRCh37 human reference (BWA-MEM v0.7.8) and processed with GATK best-practices workflow (GATK v3.4.0). The mean coverage was 35.8, it reflects the samples average. All high quality variants obtained from GATK were annotated for functional effects (intronic, intergenic, splicing, nonsynonymous, stopgain and frameshifts) based on RefSeq transcripts using Annovars. Additionally, Annovar was used to match general population frequencies from public databases (Exac, gnomAD, ESP6500, 1000g) and to

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

prioritize rare, loss-of-function variants. Linear models adjusted for PC, age and sex were conducted in PLINK. **Results** We report elevated levels of CXCL16 in a set of COVID-19 hospitalized patients. Baseline demographics of the studied cohort are presented in **Table 1**. Clinical characteristics are provided in **Table 2**. Specifically, we report significantly elevated levels of CXCL16 in a subset of COVID-19 severe (as defined by WHO scale) hospitalized patients ((P-value<0.02) displayed on Figure 1). The most significant difference reported in plasma CXCL16 between most severe (WHO- 2) COVID-19 hospitalized cases and less severe patients (P-value<0.02) as well as most severe and controls. We furthermore report a larger variance within the cases, signifying further necessity of stratification based on clinical characteristics (ANCOVA p-value -0.001, covariates: age, sex, BMI). The effect is not driven by age nor BMI, or sex (Figure 2 – Supplemental Material). We further investigated the correlation between IFN- $\gamma$ , TNF- $\alpha$ . We report lack thereof at baseline (Figure 3 – Supplemental Material). We were able to replicate the lead variant association (rs10490770) in our cohort of hospitalized patients (cases n 140 control n

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

1900) with confirmed COVID-19 infection (OR 1.9, CI 1.2-3.5, P-value <0.002). The carriers of this variant were at higher risk, of being in the hospitized severe group (as defined by the WHO scale), finding which is consistent across multiple COVID-19 GWAS results reported thus far. Moreover, we inspected the association between the lead variant status and directly CXCL16 plasma levels. This association between lead coding variant carrier status and CXCL16 levels did not attain statistical significance (result that is trending), a finding that warrants further replication in a larger sample size. FYCO1 variant within the extended haplotype did attain statistical significance (P-value <0.0001) and the result is displayed in Supplementary Figure 4. **Discussion** Previously it was demonstrated that circulating CD8+CXCR6+ T cells were significantly elevated with advanced age, yet virtually absent in patients with severe COVID-19. In a smaller sample set, plasma levels of CXCL16 were significantly upregulated in severe COVID-19 patients compared to mild COVID-19 patients 10. Differential expression of CXCR6 and CXCL16 mRNA was observed in severe COVID-19 compared to mild disease and significant functional polymorphisms in *CXCR6* are linked to viral control<sup>1</sup>. Furthermore, based on lung tissue autopsy data, the top differentially expressed genes from GWAS hits included FYCO1, specifically in AT2 cells, ciliated cells, and club cells<sup>11</sup>. FYCO1 coding variant (rs33910087) is an eQTL for CXCR6, whereas CXCR6 was differentially expressed in lung CD8 T cells in COVID-19 infected lung tissue<sup>11</sup>.

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201


202

Prior studies studies targeting the axis (both knockout and pharmacological blocking) support the hypothesis that antagonism may constitute potential therapies<sup>6</sup>. It may be the case that the treatment of the hyper-expression of the CXCL16/CXCR6 axis hence reduction of the severely heighteed homing signal may elicit such therapeutic effects, for example in a cytokine storm. Besides the potential implications in lung injury, both the CXCR6 and its ligand plays an important role in mediating a proinflammatory microenvironment for tumor growth in hepatocellular carcinoma<sup>12</sup>. Here targeting the CXCR6/CXCL16 axis is needed to elucidate the mechanism whereby neutrophils are affected in the tumor environment<sup>12</sup>. Authors propose one such orally bioavailable compound - antagonist of the CXCR6 receptor shown to decrease growth in a mouse xenograft model of hepatocellular carcinoma<sup>12</sup>. Further studies on antagonism of the axis are needed to explain the timing of such antagonism treatment that would result in optimal outcomes. Our current study, is the largest thus far reporting on the plasma levels of CXCL16 in association with severity in COVID-19 patients. The results support the significant role of the CXCR6/CXCL16 axis in the immunopathogenesis of severe COVID-19. Further studies warrant analysis of outcomes based on the carrier status for this locus and on the levels of CXCL16.


203 204 205 206 References 207 208 Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. 1. 209 medRxiv. 2020;17(8):25. https://doi.org/10.1101/2020.09.24.20200048. 210 2. Initiative C-19 HG. Mapping the human genetic architecture of COVID-19. Nature. 2021. 211 doi:10.1038/s41586-021-03767-x 212 3. Nakanishi T, Pigazzini S, Degenhardt F, et al. Age-dependent impact of the major common genetic 213 risk factor for COVID-19 on severity and mortality. medRxiv. 2021. 214 doi:10.1101/2021.03.07.21252875 215 Collado A, Marques P, Escudero P, et al. Functional role of endothelial CXCL16/CXCR6-platelet-216 leucocyte axis in angiotensin II-associated metabolic disorders. Cardiovascular Research. 217 2018;114(13):1764-1775. doi:10.1093/cvr/cvy135 Abel S, Hundhausen C, Mentlein R, et al. The Transmembrane CXC-Chemokine Ligand 16 Is 218 5. 219 Induced by IFN-y and TNF- $\alpha$  and Shed by the Activity of the Disintegrin-Like Metalloproteinase 220 ADAM10. The Journal of Immunology. 2004;172(10):6362 LP-6372. doi:10.4049/jimmunol.172.10.6362 221 222 6. Tu G-W, Ju M-J, Zheng Y-J, et al. CXCL16/CXCR6 is involved in LPS-induced acute lung injury via 223 P38 signalling. Journal of cellular and molecular medicine. 2019;23(8):5380-5389. 224 doi:10.1111/jcmm.14419 225 7. Ashhurst AS, Flórido M, Lin LCW, et al. CXCR6-Deficiency Improves the Control of Pulmonary 226 Mycobacterium tuberculosis and Influenza Infection Independent of T-Lymphocyte Recruitment 227 to the Lungs. Frontiers in Immunology. 2019;10:339. doi:10.3389/fimmu.2019.00339 228 8. Blaak H, Boers PHM, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus ADME. CCR5, 229 GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants 230 isolated from individuals with and without plasma viremia. Journal of virology. 2005;79(3):1686-1700. doi:10.1128/JVI.79.3.1686-1700.2005 231 232 9. Wein AN, McMaster SR, Takamura S, et al. CXCR6 regulates localization of tissue-resident 233 memory CD8 T cells to the airways. Journal of Experimental Medicine. 2019;216(12):2748-2762. 234 doi:10.1084/jem.20181308 235 10. Payne DJ, Dalal S, Leach R, et al. The CXCR6/CXCL16 axis links inflamm-aging to disease severity in 236 COVID-19 patients. bioRxiv. January 2021:2021.01.25.428125. doi:10.1101/2021.01.25.428125 237 Delorey TM, Ziegler CGK, Heimberg G, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology 11. 238 and cellular targets. Nature. 2021;595(7865):107-113. doi:10.1038/s41586-021-03570-8


Peddibhotla S, Hershberger PM, Jason Kirby R, et al. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma. Bioorganic & medicinal chemistry letters. 2020;30(4):126899. doi:10.1016/j.bmcl.2019.126899 Figure 1 Baseline plasma CXCL16 levels in association with severity of COVID-19 manifestation and case control analysis. Severe (as defined by WHO scale) cases had significantly higher levels of CXCL16 – effect that is statistically significant.

# **CXCL16** baseline




**Supplemental Figure 2** Scatter plot between CXCL16 and IFNg and TNFa (baseline samples collected from COVID-19 hospitlized patients with severity determined with WHO scale)





**Supplemental Figure 3** Correlation between age and CXCL16 plasma levels (collected at baseline form COVID-19 hospilized patients)



**Supplemental Figure 4** Association between genotype status and CXCL16 plasma levels (collected at baseline form COVID-19 hospilized patients)

# FYCO1 3UTR rs60431156 vs CXCL16




Table 1

Characteristic	Total (N=141)
Age (years)	64 (54 - 72)
Sex, n (%)	
Male	91 (64.5)
Female	50 (35.5)
Race, n (%)	
Asian	2 (1.4)
Black or African American	35 (24.8)
Native Hawaiian or Other Pacific Islander	1 (0.7)
White	73 (51.8)
Other	30 (21.3)
Any Comorbidities, n (%)	135 (95.7)
Hypertension	80 (56.7)
Diabetes	56 (39.7)
Coronary Heart Disease	10 (7.1)
Asthma	16 (11.3)
7 Point Ordinal Scale at Baseline, n (%)	
2 - Hospitalized on mechanical ventilation or ECMO	8 (5.7)
3 - Hospitalized on non-invasive ventilation or high-flow oxygen supplement	69 (48.9)
4 - Hospitalized requiring supplemental oxygen	61 (43.3)
5 - Hospitalized not requiring supplemental oxygen, requiring continued medical care	3 (2.1)

Characteristic	Total (N=141)
Time from Hospitalization to Starting Study Treatment, Days	4 (2 - 7)
Early (<=10 Days from Hospitalization)	127 (90.1)
Late (>10 Days from Hospitalization)	14 (9.9)
Highest Oxygen Therapy Support	
Room Air	3 (2.1)
Nasal Cannula (NC)	46 (32.6)
Non Rebreather (NRB)	15 (10.6)
High Flow Nasal Cannula (HFNC)	52 (36.9)
CPAP Mask	7 (5.0)
BiPAP Mask	10 (7.1)
Mechanical Ventilation	8 (5.7)
Concomitant Medications, n (%)*	39 (27.7)
Azithromycin	19 (13.5)
Tocilizumab	4 (2.8)
Hydroxychloroquine	12 (8.5)
Steroids#	21 (14.9)